Investors

Mindset is developing next-generation psychedelic medicines and related manufacturing processes to help treat neuropsychiatric patients with unmet needs.

Advancing an IP portfolio of innovative new psychedelic medicines that leverage clinical research into classic psychedelic drugs:
Lead Compound MSP-1014 demonstrating superior preclinical characteristics in head-to-head comparison with psilocybin
4 patent-pending new drug families drawing on novel chemical structures;
Over 75 compounds synthesized with preclinical data demonstrating promising results; and
Synthesis process for psilocybin demonstrating clear benefits over known processes.

Download Presentation

Press Releases & News

The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines

January 5, 2022

Mindset to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022

January 4, 2022

Mindset Pharma Recaps 2021 Milestones and Highlights

December 30, 2021

Upcoming Events

No items found.

2021 Annual and Special Meeting

Analyst Coverage

Firm

Maxim Group LLC

H.C. Wainwright & Co.

Analyst

Jason McCarthy, Ph.D.

Patrick R. Trucchio, CFA

Mindset Pharma Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Mindset Pharma Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Mindset Pharma Inc. or its management. Mindset Pharma Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.